<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03938272</url>
  </required_header>
  <id_info>
    <org_study_id>OC5-OL-02</org_study_id>
    <nct_id>NCT03938272</nct_id>
  </id_info>
  <brief_title>An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria</brief_title>
  <acronym>ePHex-OLE</acronym>
  <official_title>An Open-label Single-arm Treatment Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact for Patients With Primary Hyperoxaluria Who Completed Study OC5-DB-02</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OxThera</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OxThera</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OC5-OL-02 (ePHex-OLE) is a 2 year, open-label, extension study to evaluate the long-term&#xD;
      efficacy and safety of Oxabact OC5 for patients with primary hyperoxaluria who completed&#xD;
      study the parent double-blind, placebo-controlled study OC5-DB-02 (ePHex).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Parent, pivotal study (OC5-DB-02) did not meet primary endpoint. No safety concerns for early&#xD;
    termination.&#xD;
  </why_stopped>
  <start_date type="Actual">April 3, 2019</start_date>
  <completion_date type="Actual">July 14, 2021</completion_date>
  <primary_completion_date type="Actual">July 14, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label study in which all patients will receive Oxabact OC5</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in kidney function (eGFR) after 12 and 24 months of open-label Oxabact treatment</measure>
    <time_frame>104 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Hyperoxaluria, Primary</condition>
  <arm_group>
    <arm_group_label>Oxabact OC5 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxabact OC5 - Oxalobacter formigenes Strain HC-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Oxabact OC5 - Oxalobacter formigenes Strain HC-1</intervention_name>
    <description>Live, commensal bacteria</description>
    <arm_group_label>Oxabact OC5 capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent (as applicable for the age of the subject).&#xD;
&#xD;
          2. Participation in and completion of study OC5-DB-02.&#xD;
&#xD;
          3. Subjects who had received vitamin B6 during OC5-DB-02 study should maintain a stable&#xD;
             dose. Subjects not receiving vitamin B6 during OC5-DB-02 must be willing to refrain&#xD;
             from initiating pyridoxine during study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to swallow size 4 capsules.&#xD;
&#xD;
          2. Use of antibiotics to which O. formigenes is sensitive.&#xD;
&#xD;
          3. Current treatment with a separate ascorbic acid preparation.&#xD;
&#xD;
          4. Pregnant women (or women who are planning to become pregnant).&#xD;
&#xD;
          5. Women of childbearing potential who are not using adequate contraceptive precautions.&#xD;
&#xD;
          6. Presence of a medical condition that the Investigator considers likely to make the&#xD;
             subject susceptible to adverse effect of study treatment or unable to follow study&#xD;
             procedures or any condition that is likely to interfere with the study drug mechanism&#xD;
             of action (such as abnormal GI function).&#xD;
&#xD;
          7. Participation in any interventional study of another investigational product,&#xD;
             biologic, device, or other agent or not willing to forego other forms of&#xD;
             investigational treatment during this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindernierenzentrum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 6, 2021</submitted>
    <returned>November 3, 2021</returned>
    <submitted>November 11, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

